Literature DB >> 10845666

Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.

M A Khan1, C S Combs, E M Brunt, V J Lowe, M K Wolverson, H Solomon, B T Collins, A M Di Bisceglie.   

Abstract

BACKGROUND/AIMS: 18F-fluorodeoxyglucose uptake allows estimation of glucose metabolism by tumor cells using positron emission tomography (PET). We evaluated the role of PET imaging in the diagnosis of hepatocellular carcinoma.
METHODS: PET images were collected after intravenous injection of 8-12 mCi of 18F-FDG in 20 patients with hepatocellular carcinoma (HCC). PET tumor activity level was assessed on a scale of 1 to 4 compared to normal liver tissue. The PET score was compared with abdominal computerized tomography (CT) scan results and between tumors of different grades and differentiation.
RESULTS: Of the 20 patients studied, 11 (55%) had positive PET scans (PET score: 3 or 4) while nine (45%) were negative (PET score: 1 or 2). CT scan was positive in 18 patients (90%) and negative in two (10%). PET, however, revealed metastases in three patients that were not seen on CT. On pathological review, well-differentiated and low-grade tumors had lower PET scores. Comparison of the well-differentiated with the moderately- and poorly-differentiated tumors revealed a statistically significant difference. No statistical significance was observed between the moderately- and poorly-differentiated tumors or between different tumor grades and PET scores.
CONCLUSIONS: The sensitivity of PET in diagnosis of HCC was 55% compared to 90% for CT scanning, although only PET detected some tumors (including distant metastases). Well-differentiated and low tumor grades had lower activity on PET and correspondingly lower PET scores. PET imaging may help assess tumor differentiation and may be useful in the diagnosis and staging and prognostication of HCC as an adjunct to CT.

Entities:  

Mesh:

Year:  2000        PMID: 10845666     DOI: 10.1016/s0168-8278(00)80248-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  100 in total

Review 1.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  18F-FDG PET for hepatocellular carcinoma presenting with portal vein tumor thrombus.

Authors:  Kazuyuki Hanajiri; Hiroshi Mitsui; Toshiyuki Maruyama; Yuji Kondo; Shuichiro Shiina; Masao Omata; Keiichi Nakagawa
Journal:  J Gastroenterol       Date:  2005-10       Impact factor: 7.527

3.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

Review 5.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 6.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

7.  18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Authors:  Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

Review 8.  Imaging of liver cancer.

Authors:  Ben Ariff; Claire R Lloyd; Sameer Khan; Mohamed Shariff; Andrew V Thillainayagam; Devinder S Bansi; Shahid A Khan; Simon D Taylor-Robinson; Adrian K P Lim
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

9.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

10.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.